Citations

Showing 10 of 108104 citations.

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Ko, Andrew H. , Chiorean, E. Gabriela , Kwak, Eunice L., Lenz, Heinz‐Josef , Nadler, Paul I., Wood, Debra L., Fujimori, Masamoto, Inada, Tetsuhi, Kouji, Hiroyuki , Fujimori, Masamoto, McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15721-e15721

10.1200/jco.2016.34.15_suppl.e15721 Get It

The prognostic impact of proinflammatory markers (NLR, PLR) in biliary cancer.
Padrnos, Leslie , Thind, Komal, Barrett, Brandon, Mounajjed, Taofic, Lam‐Himlin, Dora , Kosiorek, Heidi , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15621-e15621

10.1200/jco.2016.34.15_suppl.e15621 Get It

DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny.
Zhang, Jianping , Tamboli, Pheroze, Allanick, Frederick, Khayat, David, Wood, Christopher G. , Malouf, Gabriel G. , Su, Xiaoping , Ho, Thai H. , Lu, Yue , Raynal, Noël J.‐M. , Karam, Jose Antonio , Mouawad, Roger , Jelı́nek, Jaroslav , Tannir, Nizar

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4512-4512

10.1200/jco.2016.34.15_suppl.4512 Get It

ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.
Puligandla, Mäneka, Manola, Judith , Pins, Michael, Vuky, Jacqueline , Carthon, Bradley Curtis , Pitot, Henry C., Kuzel, Timothy M. , DiPaola, Robert S. , ECOG/ACRIN, Haas, Naomi B , McDermott, David F. , Dutcher, Janice P. , Carducci, Michael A. , Plimack, Elizabeth R. , Appleman, Leonard J. , ECOG/ACRIN

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4511-4511

10.1200/jco.2016.34.15_suppl.4511 Get It

GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).
Evans, T.R. Jeffry , Nakamura, Kenichi , Honma, Yoshitaka , Tije, Albert J. ten , Anthoney, David Alan, Boyd, Ruth , Graham, Janet , Nicoll, J. J., Salto‐Tellez, Manuel , Starling, Naureen , Ueno, Makoto , Yim, Kein, Aparicio, Thomas , Malicot, Karine Le , McWilliams, Robert R. , Dixon-Hughes, Judith , Iveson, Timothy , Paul, James , Yim, Kein-Leong , Bridgewater, John , Wilson, Richard H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS4154-TPS4154

10.1200/jco.2016.34.15_suppl.tps4154 Get It

PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Galle, Peter R. , Luca, Angelo , Pelusio, Adina, Agathon, Delphine , Lusky, Monika, Breitbach, Caroline J. , Galle, Peter Robert , Abou‐Alfa, Ghassan K. , Chao, Yee , Brown, Karen T. , Heo, Jeong , Borad, Mitesh J. , Burke, James, Qin, Shukui

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS4146-TPS4146

10.1200/jco.2016.34.15_suppl.tps4146 Get It

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Vonderheide, Robert H. , Wolff, Robert A. , Giordano, Heidi, Goble, Sandra, Shroff, Rachna T. , Domchek, Susan M. , McWilliams, Robert R. , Biankin, Andrew V. , Alberts, Steven R. , Lin, Kevin

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2016.34.15_suppl.4110 Get It

Genetic heterogeneity and survival among pancreatic adenocarcinoma (PDAC) patients with positive family history.
Petersen, Gloria M. , Chaffee, Kari G. , Majithia, Neil , Allen, Brian, Singh, Nanda, Hartman, Anne‐Renee , Oberg, Ann L. , McWilliams, Robert R. , Kidd, John

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4108-4108

10.1200/jco.2016.34.15_suppl.4108 Get It

Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
O’Neil, Bert H. , Starodub, Alexander, Jonker, Derek J. , Edenfield, William J. , El‐Rayes, Bassel F. , Hálfdánarson, Þorvarður R. , Ramanathan, Ramesh K., Pitot, Henry C., Britten, Carolyn D., Adesunloye, Bamidele, Borodyansky, Laura, Li, Chiang, El-Rayes, Bassel F , Halfdanarson, Thorvardur R , Hubbard, Joleen M. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3564-3564

10.1200/jco.2016.34.15_suppl.3564 Get It

Commonality and clinical, pathological, and prognostic characteristics of non-V600E BRAF mutations (BRAFMut) in metastatic colorectal cancers (mCRC) compared to V600 BRAFMut CRCs.
Kipp, Benjamin R. , Voss, Jesse S. , Grothey, Axel, Jones, Jeremy C , Leal, Alexis D. , Hubbard, Joleen M. , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3529-3529

10.1200/jco.2016.34.15_suppl.3529 Get It